SEC Form 4 · accession 0001144204-16-112097
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Bright
Officer — See Remarks
Period of report
Jul 5, 2016
Accepted (ET)
Jul 7, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 5, 2016 | S | 155 | $145.1092 | D | 18,706 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.
- F2Includes a correction of 6 shares that were added to the Reporting Person's beneficial ownership of securities due to a clerical error in the documentation provided by the Reporting Person's broker of a mandatory sale that occurred on April 4, 2016 of common stock to cover the withholding tax amounts upon the vesting of such restricted stock awards.
Remarks
Chief Commercial & Corporate Affairs Officer